title: Clinical study on the application of tacrolimus and DMSO in the treatment of chronic superficial keratitis in dogs.
abstract: The objective of this study was to assess the treatment of chronic superficial keratitis (CSK) in dogs with the use of tacrolimus and DMSO. The study was conducted on 16 dogs - 7 males and 9 females, aged 3 to 11 years, diagnosed with CSK. The disease was treated with ophthalmic drops containing 0.02% tacrolimus and 50% DMSO, administered to the ocular surface three times a day. Prior to the treatment and after 5 weeks of therapy, the corneal neovascularisation, pigmentation, and also the redness and depigmentation of the third eyelid margin were assessed. The percentage of the corneal surface afflicted with inflammatory processes was calculated on the basis of photographs taken with the use of IsoCalc.com's Get Area software for Corel DRAW 12. It was found that the application of tacrolimus and DMSO caused a reduction of inflammatory process and neovascularisation in the cornea. The mean corneal surface afflicted with inflammatory processes was statistically significantly reduced from 69.9% to 43.9% (p < or = 0.01)--in case of the right corneas, and from 58.9% to 38.6% in case of the left corneas. Of 32 corneas diagnosed with the pigmentation, the reduction of the pigmentation was observed in 14, while in 16 the pigmentation increased. The treatment of CSK with the use of tacrolimus and DMSO causes the reduction in terms of inflammatory processes and neovascularisation, but in many cases does not inhibit the progress of the pigmentation.
authors: Department and Clinic of Animal Surgery, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Głeboka 30, 20-612 Lublin, Poland. balicki.ireneusz@gmail.com
authors: I
authors: I
authors: Balicki
mesh_terms: D000818:Animals; D002908:Chronic Disease; D004121:Dimethyl Sulfoxide / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007634:Keratitis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D016166:Free Radical Scavengers; D007166:Immunosuppressive Agents; D016559:Tacrolimus; D004121:Dimethyl Sulfoxide